<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35361525</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-2364</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neuromuscular disorders : NMD</Title>
          <ISOAbbreviation>Neuromuscul Disord</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical and neuroradiological correlates of sleep in myotonic dystrophy type 1.</ArticleTitle>
        <Pagination>
          <StartPage>377</StartPage>
          <EndPage>389</EndPage>
          <MedlinePgn>377-389</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nmd.2022.02.003</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0960-8966(22)00036-0</ELocationID>
        <Abstract>
          <AbstractText>Abnormalities of sleep are common in myotonic dystrophy type 1 (DM1), but few previous studies have combined polysomnography with detailed clinical measures and brain imaging. In the present study, domiciliary polysomnography, symptom questionnaires and cognitive evaluation were undertaken in 39 DM1-affected individuals. Structural brain MRI was completed in those without contra-indication (n = 32). Polysomnograms were adequate for analysis in 36 participants. Sleep efficiency was reduced, and sleep architecture altered in keeping with previous studies. Twenty participants (56%) had moderate or severe sleep-disordered breathing (apnoea-hypopnoea index [AHI] ≥ 15). In linear modelling, apnoeas were positively associated with increasing age and male sex. AHI ≥ 15 was further associated with greater daytime pCO<sub>2</sub> and self-reported physical impairment, somnolence and fatigue. Percentage REM sleep was inversely associated with cerebral grey matter volume, stage 1 sleep was positively associated with occipital lobe volume and stage 2 sleep with amygdala volume. Hippocampus volume was positively correlated with self-reported fatigue and somnolence. Linear relationships were also observed between measures of sleep architecture and cognitive performance. Findings broadly support the hypothesis that changes in sleep architecture and excessive somnolence in DM1 reflect the primary disease process in the central nervous system.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hamilton</LastName>
            <ForeName>Mark J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>West of Scotland Clinical Genetics Service, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK; Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK. Electronic address: mark.hamilton@ggc.scot.nhs.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Atalaia</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Sorbonne Université, Inserm, Center of Research in Myology, UMRS 974, Institut de Myologie, G.H . Pitié-Salpêtrière, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McLean</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroradiology, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cumming</LastName>
            <ForeName>Sarah A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Evans</LastName>
            <ForeName>Jonathan J</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Health and Wellbeing, University of Glasgow, Gartnavel Royal Hospital, Glasgow, UK G12 0XH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ballantyne</LastName>
            <ForeName>Bob</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>West of Scotland Clinical Genetics Service, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jampana</LastName>
            <ForeName>Ravi</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroradiology, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>The Scottish Myotonic Dystrophy Consortium</LastName>
            <AffiliationInfo>
              <Affiliation>West of Scotland Clinical Genetics Service, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Longman</LastName>
            <ForeName>Cheryl</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>West of Scotland Clinical Genetics Service, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Livingston</LastName>
            <ForeName>Eric</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Glasgow Royal Infirmary, Glasgow G4 0SF, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van der Plas</LastName>
            <ForeName>Ellen</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, IA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koscik</LastName>
            <ForeName>Timothy</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, IA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nopoulos</LastName>
            <ForeName>Peggy</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, IA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Farrugia</LastName>
            <ForeName>Maria Elena</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Monckton</LastName>
            <ForeName>Darren G</ForeName>
            <Initials>DG</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>CAF/MD/15/01</GrantID>
            <Acronym>CSO_</Acronym>
            <Agency>Chief Scientist Office</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Neuromuscul Disord</MedlineTA>
        <NlmUniqueID>9111470</NlmUniqueID>
        <ISSNLinking>0960-8966</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006970" MajorTopicYN="Y">Disorders of Excessive Somnolence</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009223" MajorTopicYN="Y">Myotonic Dystrophy</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077260" MajorTopicYN="N">Sleepiness</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Myotonic dystrophy</Keyword>
        <Keyword MajorTopicYN="N">Polysomnography</Keyword>
        <Keyword MajorTopicYN="N">Sleep-disordered breathing</Keyword>
        <Keyword MajorTopicYN="N">structural MRI</Keyword>
      </KeywordList>
      <CoiStatement>Conflicts of interest Within the last five years Professor Monckton has been a scientific consultant and/or received an honoraria/stock options/grants from AMO Pharma, Charles River, LoQus23, Small Molecule RNA, Triplet Therapeutics and Vertex Pharmaceuticals. Professor Monckton also had research contracts with AMO Pharma and Vertex Pharmaceuticals. Professor Monckton has received research grants/contracts from the European Union, CHDI, European Huntington Disease Network, Huntington Disease Society of America, National Institute of Health, Muscular Dystrophy UK and the Myotonic Dystrophy Support Group. Professor Monckton is on the Scientific Advisory Board of Myotonic (formerly the Myotonic Dystrophy Foundation) and EuroDyMA (European Dystrophia Myotonica Association), is a scientific advisor to the Myotonic Dystrophy Support Group and is a vice president of Muscular Dystrophy UK.; The remaining authors have no conflicts to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>5</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35361525</ArticleId>
        <ArticleId IdType="doi">10.1016/j.nmd.2022.02.003</ArticleId>
        <ArticleId IdType="pii">S0960-8966(22)00036-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
